A representative of arylcyanomethylenequinone oximes effectively inhibits growth and formation of hyphae in Candida albicans and influences the activity of protein kinases in vitro

• Published in: Saudi pharmaceutical journal 2018-02, Vol.26 (2), p.244-252
• Main Authors: Masłyk, Maciej, Janeczko, Monika, Demchuk, Oleg M., Boguszewska-Czubara, Anna, Golczyk, Hieronim, Sierosławska, Anna, Rymuszka, Anna, Martyna, Aleksandra, Kubiński, Konrad
• Format: Article
• Language: English
• Subjects: Antifungal agents; Arylcyanomethylenequinone oximes; Candida albicans; Hyphae; Original; Phosphorylation
• ISSN: 1319-0164; 2213-7475
• DOI: 10.1016/j.jsps.2017.12.004

In this study, we applied various assays to reveal new activities of phenylcyanomethylenequinone oxime-4-(hydroxyimino) cyclohexa-2,5-dien-1-ylidene](phenyl)ethanenitrile (4-AN) for potential anti-microbial applications. These assays demonstrated (a) the antimicrobial effect on bacterial and fungal cultures, (b) the effect on the in vitro activity of the kinase CK2, (c) toxicity towards human erythrocytes, the Caco-2 cancer cell line, and embryonic development of Zebrafish. We demonstrated the activity of 4-AN against selected bacteria and Candida spp. The MIC ranging from 4 µg/ml to 125 µg/ml proved effective in inhibition of formation of hyphae and cell aggregation in Candida, which was demonstrated at the cytological level. Noteworthy, 4-AN was found to inhibit the CK2 kinase with moderate potency. Moreover, at low concentrations, it did not exert any evident toxic effects on human erythrocytes, Caco-2 cells, or Zebrafish embryos. 4-AN can be a potential candidate as a novel drug against Candida infections.